AbCellera Biologics (ABCL) EPS (Basic) (2020 - 2023)
AbCellera Biologics' EPS (Basic) history spans 4 years, with the latest figure at -$0.17 for Q4 2023.
- For the quarter ending Q4 2023, EPS (Basic) fell 70.0% year-over-year to -$0.17, compared with a TTM value of -$0.17 through Sep 2024, up 62.22%, and an annual FY2024 reading of -$0.55, down 7.84% over the prior year.
- EPS (Basic) for Q4 2023 was -$0.17 at AbCellera Biologics, down from -$0.1 in the prior quarter.
- The five-year high for EPS (Basic) was $0.59 in Q1 2022, with the low at -$0.17 in Q4 2023.
- Average EPS (Basic) over 4 years is $0.07, with a median of -$0.02 recorded in 2020.
- Year-over-year, EPS (Basic) soared 4400.0% in 2021 and then plummeted 450.0% in 2023.
- Tracing ABCL's EPS (Basic) over 4 years: stood at $0.52 in 2020, then crashed by 57.69% to $0.22 in 2021, then crashed by 145.45% to -$0.1 in 2022, then crashed by 70.0% to -$0.17 in 2023.
- Per Business Quant, the three most recent readings for ABCL's EPS (Basic) are -$0.17 (Q4 2023), -$0.1 (Q3 2023), and -$0.11 (Q2 2023).